Mechanism of Action for WELIREG™ (belzutifan)
WELIREG is a selective HIF-2α inhibitor, which works in the nucleus and may reduce the transcription of certain target genes that drive tumor growth in VHL disease
![Mechanism of Action for WELIREG™ (belzutifan): WELIREG Binds to HIF-2α, Which Blocks Interaction With HIF-1β and May Reduce Downstream Activities of Cellular Proliferation Angiogenesis, and Tumor Growth](/static/mechanism-of-action-638debe5bbefb518d7a46fdceea9870e.webp)
![Mechanism of Action for WELIREG™ (belzutifan): WELIREG Binds to HIF-2α, Which Blocks Interaction With HIF-1β and May Reduce Downstream Activities of Cellular Proliferation Angiogenesis, and Tumor Growth](/static/mechanism-of-action-mobile-a702138a6e5dd2472fd38efee82140df.png)
As a selective HIF-2α inhibitor, WELIREG is the only approved systemic tumor management option for patients with certain VHL disease–associated tumors1,2
References: 1. Narayan V, Jonasch E. Systemic therapy development in von Hippel-Lindau disease: an outsized contribution from an orphan disease. Cancers (Basel). 2022;14(21):5313. 2. Center for Drug Evaluation and Research. Advancing Health Through Innovation: New Drug Therapy Approvals 2021. https://www.fda.gov/media/155227/download. Accessed February 6, 2024.